A Randomized Phase III Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide VINO-AC Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide VINO-CPO vs Vincristine, Dactinomycin and Cyclophosphamide VAC plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma HR-RMS

Brief Summary

Type:
Sarcomas

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04994132

Study #:
CMH - ARST2031

Start Date:
Aug 22, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04994132

View Complete Trial Details & Eligibility at ClinicalTrials.gov